➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Express Scripts
Baxter
Merck
Colorcon

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

FERRIC OXYHYDROXIDE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for ferric oxyhydroxide and what is the scope of patent protection?

Ferric oxyhydroxide is the generic ingredient in eight branded drugs marketed by Am Regent, Sanofi Aventis Us, Allergan, New River, West-ward Pharms Int, and Vifor Fresenius, and is included in eight NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ferric oxyhydroxide has ninety patent family members in thirty-three countries.

There are twenty drug master file entries for ferric oxyhydroxide. Nine suppliers are listed for this compound.

Pharmacology for FERRIC OXYHYDROXIDE

US Patents and Regulatory Information for FERRIC OXYHYDROXIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sanofi Aventis Us IRON DEXTRAN ferric oxyhydroxide INJECTABLE;INJECTION 010787-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Am Regent DEXFERRUM ferric oxyhydroxide INJECTABLE;INJECTION 040024-001 Feb 23, 1996 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
New River PROFERDEX ferric oxyhydroxide INJECTABLE;INJECTION 017807-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FERRIC OXYHYDROXIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Am Regent DEXFERRUM ferric oxyhydroxide INJECTABLE;INJECTION 040024-001 Feb 23, 1996 ⤷  Free Forever Trial ⤷  Free Forever Trial
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Express Scripts
Baxter
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.